Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,716.40
(
-0.02%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
106.44
(
1.92%
)
Bitcoin
70,786.88
(
1.27%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 122640

Thursday, 06/30/2011 12:34:25 AM

Thursday, June 30, 2011 12:34:25 AM

Post# of 257262
GILD—If GS7340 pans out, it will remove some of the pressure on GILD’s shares from worry about the loss of Viread patent protection in 2017.

Other than the 5914331 patent, the Emtriva Orange-Book patents still in effect after Viread goes off-patent are unlikely to protect Truvada (and Atripla) from generic competition, IMO (#msg-5914331).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today